Q4 2024 Legend Biotech Corp Earnings Call Transcript
Key Points
- Legend Biotech Corp (LEGN) reported a 110% year-over-year increase in net trade sales of CARVYKTI, reaching approximately $334 million in the fourth quarter of 2024.
- CARVYKTI has demonstrated a unique clinical profile, being the first and only CAR-T therapy in multiple myeloma to show a survival benefit versus standard of care.
- The company has expanded its manufacturing capacity, with the FDA approving the Novartis facility in New Jersey for commercial production of CARVYKTI.
- Legend Biotech Corp (LEGN) has successfully increased the number of certified hospitals in the US to 102, enhancing its treatment reach.
- The company is on track to achieve operational breakeven for CARVYKTI by the end of 2025 and anticipates company-wide profitability in 2026, excluding unrealized foreign exchange gains or losses.
- Legend Biotech Corp (LEGN) reported a net profit primarily driven by an unrealized foreign exchange gain, indicating potential volatility in financial results due to currency fluctuations.
- Research and development expenses remained high at $104 million for the fourth quarter, reflecting ongoing costs associated with pipeline development.
- The company faces competition from upcoming BCMA bispecifics, which could impact CARVYKTI's market share in the future.
- Despite strong sales growth, the company is still in a supply-constrained environment in Europe, which could limit revenue potential.
- Legend Biotech Corp (LEGN) is investing heavily in expanding its manufacturing capacity, which could strain financial resources if demand projections are not met.
Good day, and welcome to the Legend Biotech fourth quarter and full year 2024 earnings call. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to turn the call over to Caroline Paul, Associate Director of Investor Relations. Please go ahead.
Good morning. This is Caroline Paul, Associate Director of Investor Relations at Legend Biotech. Thank you for joining our conference call today to review our fourth quarter of 2024 performance. Prior to this call, we issued a press release announcing our financial results for the quarter. You can find the press release on our IR website at legendbiotech.com. Joining me on today's call are Ying Huang, the company's Chief Executive Officer; and Jessie Yeung, the company's Interim Chief Financial Officer.
Following the prepared remarks, we will open up the call for Q&A. We have our President of CARVYKTI, Alan Bash, President of R&D, Guowei Fang; and Chief Medical Officer,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
